Navigation Links
Colony in Biological Technology

UC Riverside researcher develops novel method to grow human embryonic stem cells

... called Rho-Rock, which the hESCs use during colony formation and which plays an important role in ... pathway, they found, as expected, that the normal colony formation of hESCs was considerably impaired. ... now, it was generally assumed that the hESC colony formation was pivotal for maintaining ...

New Weapon in BioDefense Research: NanoLogix Kit Speeds Rapid Diagnostics of Anthrax and Bubonic Plague

... disease after inhalation. The BNP(TM) technology provided similar colony counts for anthrax in 6 hours as obtained with the traditional Petri method in 24 hours. For Bubonic plague, the BNP(TM) colony count in 24 hours was also similar to what the traditional methodology ...

New designer toxins kill Bt-resistant insect pests

... then teamed up with Tabashnik to test their modified toxins on UA's colony of Bt-resistant pink bollworms, major cotton pests. Team member ... Tim Dennehy and Yves Carrire knew the Bt-resistant pink bollworms in their colony had a mutant version of cadherin. Tabashnik said, "These resistant ...

Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology

... Indian approvals for Oncology Biopharmaceuticals i.e. GCSF (Granulocyte colony Stimulating Factor), GM-CSF (Granulocyte Macrophage colony Stimulating Factor) and IL-2 (Interleukin-2). For the latter two, Zenotech ...

Micromet Closes $80.5 Million Public Offering of Common Stock

... in a phase 1 clinical trial for the treatment of patients with cancer. MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid ...

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

... in a phase 1 clinical trial for the treatment of patients with cancer. MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid ...

Micromet Announces Pricing of Public Offering of Common Stock

... in a phase 1 clinical trial for the treatment of patients with cancer. MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid ...

Micromet Announces Public Offering of Common Stock

... in a phase 1 clinical trial for the treatment of patients with cancer. MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid ...

Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009

... in a phase 1 clinical trial for the treatment of patients with cancer. MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid ...

Micromet Added to Russell 3000 Index

... in a phase 1 clinical trial for the treatment of patients with cancer. MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid ...

Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009

... a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid ...

Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel

... a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid ...

Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO

... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009

... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110

... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Scientists discover 'dancing' algae

... matrix about half a millimetre in diameter. Each of the surface cells has two hair-like appendages known as flagella, whose beating propels the colony through the fluid and simultaneously makes them spin about an axis. The researchers found that colonies swimming near a surface can form two types ...

Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth

... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Kibow Biotech, Inc. Launches Breakthrough Probiotic Dietary Supplement for Kidney Health in USA and Canada

... (psyllium husk). Presented in an enteric-coated, gluten-free, vegetarian gel capsule, each serving of Kibow Biotics contains a total of 30 billion colony forming units (CFU). When taken orally after every meal (3 times) on a daily basis, Kibow Biotics has the potential to help maintain healthy ...

Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009

... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics

... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Spiral Biotech to Introduce New Autoplate Spiral Plating System at ASM General Meeting in May

... focuses on automating the pre-analytical and analytical steps involved with traditional microbial enumeration with a product line that includes colony counters, plating systems, anaerobic workstations, susceptibility test software, air samplers and sample prep tools. For more information, contact ...

Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research

... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008

... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Micromet to Present at the Cowen Health Care Conference on March 17, 2009

... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Buckyballs could keep water systems flowing

... membranes showed less bacterial attachment than non-treated membranes. After three days, the membranes treated with buckyballs had on average 20 colony forming units, the method by which bacterial colonies are counted. "In contrast, the number of bacterial colonies on the untreated membrane was ...

Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors

... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Micromet to Present at the BIO CEO and Investor Conference on February 10, 2009

... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

The EntreTech Forum Presents... Greening Of America - The Conversion of Bio-Agriculture, Bio-Energy, and Bio-Products to Eco-Sustainable Businesses

... from biomass. Tuesday, February 17, 2009 6:30 - 9:30 p.m. The Enterprise Center at Foley Hoag, The Bay colony Corporate Center 1000 Winter St., Ste. 4000 Waltham, MA Cost: $25. public $10. students & active military For ...

Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling

... which is being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Micromet Enters Into Agreement for Solid Tumor BiTE Antibody with Bayer Schering Pharma AG

... MT 203 being developed in collaboration with Nycomed. MT 203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias

... which is being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Micromet to Present at the RBC Capital Markets Healthcare Conference

... which is being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

J. Craig Venter Institute Researchers Publish Significant Advance in Genome Assembly Technology

... which outlined the methods and techniques used to change one bacterial species, Mycoplasma capricolum, into another, Mycoplasma mycoides Large colony (LC), by replacing one organism's genome with the other one's genome. Genome transplantation was the first essential enabling step in the field of ...

Micromet Added to NASDAQ Biotechnology Index

... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

InterMune Reports Third Quarter 2008 Financial Results and Business Highlights

... of ITMN-191 with the active moiety of polymerase inhibitor R7128 (Roche/Pharmasset) in a 14-day replicon clearance assay and in a 3-week colony formation assay resulted in clearance of the HCV replicon and reduced or suppressed the emergence of drug-resistant viral variants. These ...

Micromet, Inc. Reports Third Quarter 2008 Financial Results

... MT 203 being developed in collaboration with Nycomed. MT 203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

WEHI Spin-Out MuriGen Restructures G-CSF Antagonist Program With CSL

... Zenyth Therapeutics Limited (now part of CSL Limited) and is developing therapeutic antibodies that inhibit the activity of the cytokine granulocyte colony stimulating factor (G-CSF). The collaboration built on the discovery by Professor Ian Wicks, a clinical rheumatologist at the Walter and Eliza Hall ...

MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology

... is a MAb with potential to help patients with rheumatoid arthritis. The antibody targets the alpha sub-unit of the granulocyte-macrophage colony stimulating factor receptor (GM-CSFR). CAM-3001 is a phase 1 clinical stage program. -- ICOS - ICOS (Inducible costimulator) is a receptor on ...

Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008

... Biologics Program -- Completed clinical trial demonstrating the bioequivalence of INS-19, the company's recombinant human granulocyte colony stimulating factor (G-CSF), to Neupogen(R), an FDA-approved G-CSF product for the treatment of neutropenia that recorded 2007 sales of ...

Insmed Announces First Quarter 2008 Financial Results

... and Healthcare products Regulatory Agency to initiate a clinical trial for Insmed's most advanced FOB candidate, INS-19 (Granulocyte colony Stimulating Factor or G-CSF), a FOB of the FDA-approved product Neupogen(R), which had U.S. sales of approximately $0.9 billion in ...
Other Contents
(Date:4/23/2014)... many social mammals, ravens form different types of social ... and they also form strict dominance relations. From a ... a key ability in daily social life ("knowing who ... group members have with each other sets the stage ... results of this study have been published in the ...
(Date:4/23/2014)... is leading a 2 million Food Standards Agency (FSA) ... premises and industry workers. , Norovirus outbreaks can ... a batch of frozen strawberries infected 11,000 people in ... understanding of which strains cause infection and which foods ... , Researchers will produce data that will help ...
(Date:4/22/2014)... secret to get your child to behave at the dinner ... Cornell study published in Eating Behaviors , found that ... bite with their front teeth such as drumsticks, whole apples, ... when these foods had been cut. "They were twice ... other kids," said Brian Wansink, Professor and Director of the ...
Breaking Biology News(10 mins):Ravens understand the relations among others 2Biting vs. chewing 2
(Date:4/22/2014)... The Association for Molecular Pathology (AMP) released a ... Diagnostics on recommendations for a molecular diagnostics ... of education. The report was prepared by the ... the AMP Training and Education Committee. "Our goal ... future medical laboratory scientists appropriately in order to ...
(Date:4/22/2014)... have found a way to block abnormal cholesterol production, ... the main cause of heart attacks and strokes and ... develops when fat builds inside blood vessels over time ... their ability to feed oxygen-rich blood to the heart ... experiments, described April 7 in the journal Circulation ...
(Date:4/22/2014)... German . , ... their mode of action is complex: In low concentrations ... while at high concentrations they can cause "oxidative stress", ... redox signaling unfolds in single cells and organelles in ... jointly by the teams of LMU Professor Martin Kerschensteiner ...
(Date:4/22/2014)... massive health care spending, a new RAND study concludes ... incentivize pharmaceutical companies and device makers to develop products ... medical technologies and their use, a new study suggests ... medical devices get created in the first place. The ... as little loss of health as possible and to ...
(Date:4/22/2014)... all seem to know who we say is neurotic and ... unable to act but simply doesn,t want to., ... of nearly 4,000 college students in 19 countries has uncovered ... and moving forward with life. Turns out that when they ... don,t like it as much as non-neurotics. Therefore persuasive communications ...
Breaking Medicine News(10 mins):Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:Neuroimaging: Live from inside the cell 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:Neurotics don't just avoid action: They dislike it 2
Other TagsOther Tags